The estimated Net Worth of M Scot Roberts is at least $1.3 million dollars as of 1 February 2024. Dr Roberts owns over 13,941 units of Altimmune Inc stock worth over $322,578 and over the last 7 years he sold ALT stock worth over $445,968. In addition, he makes $534,983 as Chief Scientific Officer at Altimmune Inc.
Dr has made over 10 trades of the Altimmune Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 13,941 units of ALT stock worth $99,957 on 1 February 2024.
The largest trade he's ever made was exercising 55,120 units of Altimmune Inc stock on 21 May 2018 worth over $4,410. On average, Dr trades about 7,777 units every 106 days since 2017. As of 1 February 2024 he still owns at least 44,990 units of Altimmune Inc stock.
You can see the complete history of Dr Roberts stock trades at the bottom of the page.
Dr. M. Scot Roberts is the Chief Scientific Officer at Altimmune Inc.
As the Chief Scientific Officer of Altimmune Inc, the total compensation of Dr Roberts at Altimmune Inc is $534,983. There are 4 executives at Altimmune Inc getting paid more, with Dr. Vipin K. Garg Ph.D. having the highest compensation of $897,696.
Dr Roberts is 62, he's been the Chief Scientific Officer of Altimmune Inc since . There are 10 older and 3 younger executives at Altimmune Inc. The oldest executive at Altimmune Inc is David Drutz, 81, who is the Independent Director.
M's mailing address filed with the SEC is C/O ALTIMMUNE, INC., 910 CLOPPER ROAD,, SUITE 201S, GAITHERSBURG, MD, 20878.
Over the last 7 years, insiders at Altimmune Inc have traded over $2,557,810 worth of Altimmune Inc stock and bought 3,362,060 units worth $23,898,779 . The most active insiders traders include Bioventures Ltd Novartis Ag..., Healthcare Capital Partners... et Mitchel Sayare. On average, Altimmune Inc executives and independent directors trade stock every 35 days with the average trade being worth of $432,889. The most recent stock trade was executed by David Drutz on 19 August 2024, trading 41,750 units of ALT stock currently worth $106,463.
altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current
Altimmune Inc executives and other stock owners filed with the SEC include: